Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Stomach Neoplasms 8Colorectal Neoplasms 7Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Melanoma 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Rectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Sarcoma 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Mesothelioma 2Lung Neoplasms 2Liver Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Anus Neoplasms 2Wilms Tumor 1Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × fludarabine phosphate × Gastrointestinal × Clear all
NCT04897321 2026-05-19

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

Phase 1 Recruiting
48 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT07411599 2026-04-23

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
28 enrolled
Gastrointestinal

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡